unrelated donors is less successful and still under clinical investigation. 5 One major complication of BMT in patients with SAA is graft rejection which can be prevented by Between 1982 and 1996, 20 patients (10 male, 10 female) with severe aplastic anemia (SAA) with a median age intensive pretransplant immunosuppressive therapy 1,2 and prolonged use of CsA post-transplant. 1,6 Previous blood of 25 years (17-37 years), received grafts from an HLAidentical sibling (n = 17), HLA-identical unrelated transfusions increase the risk of rejection by sensitizing recipients to transplantation antigens on donor cells.
donor (n = 2) or identical twin (n = 1). The median time from diagnosis to marrow transplantation (BMT) was
Donor buffy coat infusions during the first post-transplant days in addition to immunosuppression resulted in a 15 months (range 1-96 months). More than half of the patients had received more than 10 units of red blood reduced rate of graft rejection, but a higher incidence of chronic graft-versus-host disease (GVHD).
cells or platelet transfusions prior to BMT. Pretransplant immunosuppression consisted of cyclophospham-
Another complication resulting in significant morbidity and mortality after BMT is GVHD. Increasing age of ide (CY) alone (n = 10), CY in combination with total body irradiation (n = 8), and CY and antithymocyte recipient and donor and parity of donor are known risk factors for GVHD. 1,4,9 Post-transplant immunosuppression globulin (n = 2). For graft-versus-host disease (GVHD) prophylaxis methotrexate (MTX) alone (n = 9) or MTX with the combination of methotrexate (MTX) and CsA lead to a reduced incidence of acute GVHD and improved surwith cyclosporin A (n = 10) were given. One patient died on day 18 after marrow grafting due to infection; all vival. 10 In addition, transfusion with filtered, leukocytedepleted blood products and improved supportive care with other patients had complete and sustained engraftment (95%). Eight patients developed acute GVHD (42%), new antimicrobial and antiviral agents have led to increased survival rates after BMT during the last years.
1 nine patients chronic GVHD (53%) including four with extensive disease manifestation. One patient experiSince 1982, 20 patients with SAA have undergone BMT at the University Hospital of Vienna. Here, we report our enced a secondary malignancy 11 years after BMT. Eighteen patients followed for a median of 9.45 years long-term results. (0.42-14.7 years) have sustained hematological reconstitution and are alive and well with a Karnofsky performance score of at least 90%. Thus, excellent long-term Patients and methods survival and low morbidity make allogeneic or syngeneic BMT the treatment of choice for younger Patients patients with severe aplastic anemia. Keywords: aplastic anemia; allogeneic marrow transBetween January 1982 and April 1996 20 consecutive patients, 10 men and 10 women, aged 17-37 years (median plantation; long-term follow-up 25 years) with severe aplastic anemia as defined by the International Aplastic Anemia Study Group were admitted for marrow transplantation. 11 Their pretransplant characterAllogeneic marrow transplantation (BMT) and immunosupistics are shown in Table 1 . Median time from diagnosis pressive therapy with antithymocyte globulin (ATG), or of SAA to BMT was 15 months. Previous therapy consisted more recently, cyclosporin A (CsA) are the two options of methylprednisolone (n = 9), CsA (n = 1), CsA and ATG currently used in the treatment of severe aplastic anemia (n = 1), ATG, CsA, erythropoietin (Epo) and interleukin-3 (SAA).
1-4 BMT from a human leukocyte antigen (HLA)-(IL-3) (n = 1), respectively. Eight patients had not received identical sibling offers cure and leads to restoration of norany prior therapy. Eleven of 20 patients had received more mal hematopoiesis and long-term survival in 60-80% of than 10 units of red blood cells (RBC) and platelet transrecipients. between donor and recipient were present. Immunosuppressive therapy for transplantation and proCytogenetic studies tocols for GVHD prophylaxis were those used at our instiCells were obtained from aspirated BM before and after tution during the time period patients were transplanted.
transplantation. Chromosomal analyses from short-term Ten patients received cyclophosphamide (CY; 200 mg/kg cultures were performed according to standard procedures body weight; b.w. over 4 days), eight CY and total body and stained by G-banding using trypsin-Giemsa. Chromoirradiation (3-13.2 Gy) and two patients CY and ATG. 12 somal abnormalities are described according to the InterBone marrow (BM) was harvested and infused as prenational System for Human Cytogenetic Nomenclature. viously described. 13 The total number of nucleated marrow cells infused ranged from 2.7 to 8.8 (median 3.9) × 10 8 /kg of recipient b.w. The day of BM infusion was defined as Statistical methods day 0. Twelve patients received donor buffy coat cell Kaplan-Meier survival curves were drawn. infusions from days 1 to 4 after BMT as described.
8 GVHD prophylaxis consisted of MTX alone in nine patients and MTX plus CsA in 10, according to the Seattle protocol.
10
Results CsA levels were monitored by radioimmunoassay; a level of around 200 ng/ml was considered optimal. Tapering of Engraftment CsA started after day 100 if no signs of acute GVHD were noted. The clinical diagnosis of GVHD was confirmed by One patient died on day +18 and thus was not evaluable appropriate biopsies and clinically graded as 0-IV by the for engraftment. All other patients had restoration of normal criteria reported for acute GVHD 10 and as 'none', 'limited' hematopoiesis, as indicated by rising blood cell counts and or 'extensive' for chronic GVHD. 14 return of marrow cellularity within 4 weeks of marrow Patients were hospitalized in rooms with reverse isolgrafting. The median time for the ANC to reach more than ation or laminar air-flow. They received antimicrobial 0.5 × 10 9 /l was 25 (range 14-36) days after BMT. Platelet prophylaxis with nonabsorbable antibiotics and Pneucounts above 20 × 10 9 /l without the need for further transmocystis carinii prophylaxis with cotrimoxazole. For fusions were reached after a median of 38 (range 11-334) cytomegalovirus (CMV) prophylaxis, five patients were days. The last RBC transfusions were given after a median given acyclovir and nine CMV-hyperimmunoglobulin. Four of 48 (range 0-333) days after BMT. All surviving patients patients received recombinant human granulocyte colonyachieved complete and sustained hematologic reconstistimulating factor (rh G-CSF) in a dose of 10 g/kg b.w.
tution. ABO incompatibility between recipient and donor starting on day +1 until absolute neutrophil counts (ANC) did not affect erythroid regeneration. exceeded 1.0 × 10 9 /l. Packed RBC were given to maintain BM aspirates on days 28 and 100 showed trilineage the hemoglobin concentration at greater than 80 g/l, and engraftment in the surviving patients. Marrow obtained platelet transfusions to keep the platelet count above after grafting was of donor origin, as documented by the 20 × 10 9 /l. All blood products given were irradiated and exclusive presence of cells with donor karyotype on cytofrom CMV-negative donors. All patients signed an inforgenetic analysis of five patients, donor blood group in six med consent. Data were analyzed as of 30 September 1996.
patients, and VNTR-PCR in three patients. Ten patients had cytogenetic studies of BM prior to transplantation to detect chromosomal abnormalities. In nine patients no abnormalities were detected, and in one patient an inversion Documentation of hematopoietic engraftment of chromosome 7 was present. After BMT all 10 patients had normal marrow karyotypes. Peripheral blood (PB) and reticulocyte counts were conducted for all patients on a daily basis, starting 7 days before Transplant-related mortality (TRM) and GVHD disease BMT and continuing until hematopoietic recovery. Hemograms were obtained with the Sysmex NE-8000 (Toa MediOne patient given marrow from an unrelated donor died of cal, Kobe, Japan), and white blood cell (WBC) differential bacterial infection 18 days after marrow grafting despite counting was done with smears following modified Wright broad-spectrum antimicrobial therapy. Thus, TRM in staining. ANC were calculated from WBC and differential patients with SAA is 5% at our center (Table 2) . counts. BM aspirates were performed on days 28 and 100
Of the 19 patients with sustained engraftment, seven after transplantation. Engraftment was defined as ANC of developed acute GVHD grade 1 or 2 (37%) and one patient 0.5 × 10 9 /l, platelets of 20 × 10 9 /l, and independence of given marrow from an unrelated donor had acute GVHD RBC transfusions. Complete hematologic reconstitution grade 3 (5%). In six patients acute GVHD resolved without was defined as a platelet count of at least 100 × 10 9 /l and additional treatment, whereas in two patients methylhemoglobin of more than 120 g/l.
prednisolone was administered. Eighteen patients could be Engraftment of donor cells was also documented by followed for more than 100 days, and nine of them cytogenetic analyses (karyotype with banding) of recipient developed chronic GVHD (50%) including four patients marrow cells before and after transplantation, and by ampliwith extensive disease. The latter had all received donor fication of the variable number of tandem repeats (VNTR) buffy coat infusions after BMT and three of them were region within intron 40 of the von Willebrand factor gene given MTX alone for GVHD-prophylaxis. Chronic GVHD involved skin in all nine patients, mucosa in five, gastroby polymerase chain reaction as described. Karnofsky performance score of at least 90%.
Chronic GVHD Figure 1 shows the overall and disease-free survival. achieved a long-term disease-free survival rate of 95% and followed patients for a median of over 9 years after BMT.
GVHD = graft-versus-host disease; TRM = transplant-related mortality;
The only transplant-related death occurred in a patient KI = Karnofsky index.
given an unrelated marrow graft.
Older age, a prolonged interval between diagnosis and transplant, multiple transfusions, and serious infections intestinal tract and lungs in one patient each. Five of the nine patients had de novo chronic GVHD, the others had before transplant are known risk factors of transplantrelated morbidity and mortality in patients with SAA. 1, 4, 7, 9 experienced acute GVHD before. Treatment for chronic GVHD consisted of methylpredniDespite the facts that the median time from diagnosis of SAA to BMT was 15 months and thus rather long, and that solone (n = 5), long-term CsA (n = 4), azathioprine (n = 3), thalidomide (n = 1) and extracorporal photochemothermore than half of our patients had received multiple blood transfusions prior to BMT, TRM is very low in our study. apy (n = 1). Two patients are currently under immunosuppressive therapy. In four patients chronic GVHD has However, patient ages ranged from 17 to 37 years and are thus, quite young. resolved, in five patients mild complaints are still present.
No graft rejection was observed in our patients. Possible explanations for this finding are the larger BM cell doses Long-term follow-up transplanted, additional infusion of donor buffy coat cells post-transplant and inclusion of TBI in pretransplant conOne patient was lost to follow-up 60 days after marrow grafting. Thus, 18 patients are evaluable after a median ditioning of some patients as has been described. 1, 4, 7, 8 Despite the efficiency of TBI-containing conditioning observation time of 9.45 (0.42-14.7) years. Table 2 shows the long-term results. All patients have complete and sustained hematological reconstitution. Four patients experienced recurring viral infections and two patients fungal infections within 3 months after BMT. Within 12 months after BMT, five patients had viral infections, three recurrent varicella-zoster virus infections, and one patient had a fungal infection while taking steroids. Three of these patients had additional bacterial infections of the upper airways. More than 1 year after BMT two patients still experienced recurrent bacterial and three patients viral infections that resolved with appropriate therapy. At the time of infection three patients suffered from chronic GVHD and were receiving azathioprine at the time of infection. Serum immunoglobulin levels are within the normal range in all patients except one given marrow from an unrelated donor.
One patient developed a cataract 5 years after TBIcontaining immunosuppression and BMT. One patient who of the skin shoulder 11 years after BMT which manifested regimens in preventing graft rejection, higher incidences Acknowledgements of GVHD and interstitial pneumonitis were observed and We thank the dedicated nurses of our bone marrow transplantation survival was not improved. typically identical marrow donors in two patients who had
